Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database

Table 1 Two-by-two contingency table for disproportionality analysis

Drug	Target AEs	Other AEs	Total
Gemcitabine combined with albumin-bound paclitaxel	a	b	a + b
Gemcitabine	c	d	c + d
Total	a + c	b + d	a + b + c + d

Abbreviation AEs, adverse events; a, number of reports containing both the gemcitabine combined with albumin-bound paclitaxel and target adverse drug reaction; b, number of reports containing other adverse drug reaction of the gemcitabine combined with albumin-bound paclitaxel; c, number of reports containing the target adverse drug reaction of gemcitabine; d, number of reports containing other adverse drug reactions of gemcitabine

ISSN: 2050-6511